Leading pharmaceutical M&A deal value in China 2019, by acquirer

Value of leading investment deals of mergers and acquisitions(M&A) in the pharmaceutical sector in China as of 2019, by acquirer

Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

April 2020

Region

China

Survey time period

2019

Supplementary notes

*Other acquirers involved in the investment deal included OrbiMed Capital, Yongjin Capital, Hillhouse Capital, Cormorant, Vivo, Shanghai Pharma (HK).

The deal value figures refer only to the deals whereby a value has been publicly disclosed.

Citation formats
Use Statista now: Unlimited Access to All Statistics! $199 USD / Month
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Pharmaceutical industry in India "

Other statistics that may interest you Pharmaceutical industry in India

Global overview

5

General overview

6

Trade

4

Key players

5

Consumer behavior

5

Further related statistics

10
All features, all contents, at all times: Learn more about our professional solutions.
Learn more about how Statista can support your business.